A
Alcista
Alcista · 25%PDSB
$1.39
Precio del escenario
$1.600
+0.084 (+5.26%)Al cierre
Loading chart…
- Máximo
- 1.790
- Apertura
- 1.430
- Precio medio ponderado por volumen
- 1.59
- Volumen
- 16.97M
- Capitalización
- 110.40M
- Mínimo
- 1.390
- Importe
- 27.03M
- EV/EBITDA, TTM
- 0.00
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Análisis de IA of PDS Biotechnology Corp (PDSB)
ComprarPDS Biotechnology Corp is a good buy right now due to its recent surge in share price by 84.37% over the last five days and a strong retail sentiment that is extremely bullish. The current price of $1.38 is significantly below the analyst price target of $5, suggesting a potential upside of over 260%.
Métricas de valoración
El PER previsto actual de PDS Biotechnology Corp (PDSB) es 0.00, frente a su media de 5 años de -3.58.
Escenarios de precio de Alphio AI para PDSB
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.509-29stocktwitsKOD Stock Soars 178% to Record High Following Phase 3 Trial Success
8.509-21stocktwitsNant to Launch Blockchain and Tokenized Stocks
8.509-17stocktwitsPDSB Shares Surge 236% Amid Major Financing and Strategic Moves
7.509-15stocktwitsNant Capital Partners with PDS Biotech for Immunotherapy
4.508-11NASDAQ.COMPDS Biotechnology Shifts Strategic Focus
Preguntas frecuentes sobre PDSB, respondidas por Alphio AI
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
PDS Biotechnology Corp is a good buy right now due to its recent surge in share price by 84.37% over the last five days and a strong retail sentiment that is extremely bullish. The current price of $1.38 is significantly below the analyst price target of $5, suggesting a potential upside of over 260%.
Comunidad
Más ↗
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.